Edition:
United States

Otonomy Inc (OTIC.OQ)

OTIC.OQ on NASDAQ Stock Exchange Global Select Market

3.70USD
23 Apr 2018
Change (% chg)

$-0.05 (-1.33%)
Prev Close
$3.75
Open
$3.75
Day's High
$3.92
Day's Low
$3.70
Volume
20,889
Avg. Vol
81,160
52-wk High
$21.15
52-wk Low
$2.80

Select another date:

Thu, Mar 8 2018

BRIEF-Otonomy Qtrly Loss Per Share $‍0.62​

* OTONOMY REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Continue Reading

BRIEF-Otonomy Announces FDA Approval Of Otiprio For Acute Otitis Externa

* OTONOMY ANNOUNCES FDA APPROVAL OF OTIPRIO(R) FOR ACUTE OTITIS EXTERNA

BRIEF-Otonomy Sees 2017 Non-Gaap Expenses Totaling $73-$78 Million

* OTONOMY INC - EXPECTS GAAP OPERATING EXPENSES FOR 2017 TO TOTAL IN RANGE OF $95-$100 MILLION

BRIEF-Otonomy Inc Immediately Discontinuing Commercial Support For Otiprio

* OTONOMY INC - ‍ IS IMMEDIATELY DISCONTINUING COMMERCIAL SUPPORT FOR OTIPRIO WHICH IS EXPECTED TO SIGNIFICANTLY REDUCE FUTURE OPERATING EXPENSES​

BRIEF-Otonomy reports third quarter loss of $0.69 per share

* Otonomy reports third quarter 2017 financial results and provides corporate update

BRIEF-Otonomy reports positive results from averts-2 phase 3 trial of otividex™ in patients with ménière's disease

* Otonomy reports positive results from Averts-2 Phase 3 trial of Otividex™ in patients with Ménière's disease

Select another date:

Market Views

» More OTIC.OQ Market Views